Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C.

Klintmalm GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, Pomfret EA, Vargas HE, Brown R, Eckhoff D, Pruett TL, Roberts J, Mulligan DC, Charlton MR, Heffron TG, Ham JM, Douglas DD, Sher L, Baliga PK, Kinkhabwala M, Koneru B, Abecassis M, Millis M, Jennings LW, Fasola CG.

Liver Transpl. 2011 Dec;17(12):1394-403. doi: 10.1002/lt.22417.

2.

Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.

Krämer BK, Klinger M, Vítko Š, Glyda M, Midtvedt K, Stefoni S, Citterio F, Pietruck F, Squifflet JP, Segoloni G, Krüger B, Sperschneider H, Banas B, Bäckman L, Weber M, Carmellini M, Perner F, Claesson K, Marcinkowski W, Ostrowski M, Senatorski G, Nordström J, Salmela K.

Transplantation. 2012 Sep 15;94(5):492-8.

3.

Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study.

Klintmalm GB, Washburn WK, Rudich SM, Heffron TG, Teperman LW, Fasola C, Eckhoff DE, Netto GJ, Katz E.

Liver Transpl. 2007 Nov;13(11):1521-31.

4.

Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation.

Becker T, Foltys D, Bilbao I, D'Amico D, Colledan M, Bernardos A, Beckebaum S, Isoniemi H, Pirenne J, Jaray J; MARSILEA Study Group.

Transplantation. 2008 Dec 27;86(12):1689-94. doi: 10.1097/TP.0b013e31818fff64.

PMID:
19104406
5.

Steroid-free induction and preemptive antiviral therapy for liver transplant recipients with hepatitis C: a preliminary report from a prospective randomized study.

Kato T, Yoshida H, Sadfar K, Martinez E, Nishida S, Moon J, Madariaga J, Selvaggi G, Levi D, Ruiz P, Schiff E, Tzakis A.

Transplant Proc. 2005 Mar;37(2):1217-9.

PMID:
15848674
6.

Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year.

Kato T, Gaynor JJ, Yoshida H, Montalvano M, Takahashi H, Pyrsopoulos N, Nishida S, Moon J, Selvaggi G, Levi D, Ruiz P, Schiff E, Tzakis A.

Transplantation. 2007 Oct 15;84(7):829-35.

PMID:
17984834
7.

Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus-positive recipients of living donor liver transplantation.

Takada Y, Kaido T, Asonuma K, Sakurai H, Kubo S, Kiuchi T, Inomata Y, Isaji S, Tsumura H, Teramukai S, Matsubara Y, Sakabayashi S, Uemoto S.

Liver Transpl. 2013 Aug;19(8):896-906. doi: 10.1002/lt.23679.

8.

Daclizumab induction and maintenance steroid-free immunosuppression with mycophenolate mofetil and tacrolimus to prevent acute rejection of hepatic allografts.

Figueras J, Prieto M, Bernardos A, Rimola A, Suárez F, de Urbina JO, Cuervas-Mons V, Mata Mde L.

Transpl Int. 2006 Aug;19(8):641-8.

9.

Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation.

Rostaing L, Cantarovich D, Mourad G, Budde K, Rigotti P, Mariat C, Margreiter R, Capdevilla L, Lang P, Vialtel P, Ortuño-Mirete J, Charpentier B, Legendre C, Sanchez-Plumed J, Oppenheimer F, Kessler M; CARMEN Study Group.

Transplantation. 2005 Apr 15;79(7):807-14.

PMID:
15818323
10.

Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.

Ciancio G, Burke GW, Gaynor JJ, Roth D, Sageshima J, Kupin W, Tueros L, Hanson L, Rosen A, Ruiz P, Miller J.

Transplantation. 2008 Jul 15;86(1):67-74. doi: 10.1097/TP.0b013e3181734b4a.

PMID:
18622280
11.

A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C.

Jain A, Kashyap R, Demetris AJ, Eghstesad B, Pokharna R, Fung JJ.

Liver Transpl. 2002 Jan;8(1):40-6.

12.

Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil.

Washburn K, Speeg KV, Esterl R, Cigarroa F, Pollack M, Tourtellot C, Maxwell P, Halff G.

Transplantation. 2001 Nov 27;72(10):1675-9.

PMID:
11726831
13.

A prospective randomized open study in liver transplant recipients: daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids.

Otero A, Varo E, de Urbina JO, Martín-Vivaldi R, Cuervas-Mons V, González-Pinto I, Rimola A, Bernardos A, Otero S, Maldonado J, Herrero JI, Barrao E, Domínguez-Granados R.

Liver Transpl. 2009 Nov;15(11):1542-52. doi: 10.1002/lt.21854.

14.

Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicenter, prospective, pilot trial.

Abramowicz D, Vanrenterghem Y, Squifflet JP, Kuypers D, Mourad M, Meurisse M, Wissing M.

Clin Transplant. 2005 Aug;19(4):475-82.

PMID:
16008591
15.

Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study.

Saliba F, Rostaing L, Gugenheim J, Durand F, Radenne S, Leroy V, Neau-Cransac M, Calmus Y, Salamé E, Pageaux GP, Duvoux C, Taguieva N, Sinnasse-Raymond G, Sebagh M, Samuel D, Marquet P.

Transplantation. 2016 Aug;100(8):1705-13. doi: 10.1097/TP.0000000000001228.

PMID:
27454919
16.

Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C.

Wiesner RH, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Lake JR.

Liver Transpl. 2005 Jul;11(7):750-9.

17.

Two-dose daclizumab, tacrolimus, mycophenolate mofetil, and steroid-free regimen in de novo cardiac transplant recipients: early experience.

Mastrobuoni S, Ubilla M, Cordero A, Herreros J, Rabago G.

Transplant Proc. 2007 Sep;39(7):2163-6.

PMID:
17889125
18.

Steroid-free regimen with daclizumab, mycophenolate mofetil, and tacrolimus in liver transplant recipients.

Figueras J, Bernardos A, Prieto M, Gómez M, Rimola A, Ortiz de Urbina J, Cuervas-Mons V, de la Mata M, Dominguez-Granados R.

Transplant Proc. 2002 Aug;34(5):1511-3. No abstract available.

PMID:
12176461
19.

Daclizumab induction therapy associated with tacrolimus-MMF has better outcome compared with tacrolimus-MMF alone in pediatric living donor liver transplantation.

Schuller S, Wiederkehr JC, Coelho-Lemos IM, Avilla SG, Schultz C.

Transplant Proc. 2005 Mar;37(2):1151-2.

PMID:
15848653
20.

Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation.

Ekberg H, Bernasconi C, Tedesco-Silva H, Vítko S, Hugo C, Demirbas A, Acevedo RR, Grinyó J, Frei U, Vanrenterghem Y, Daloze P, Halloran P.

Am J Transplant. 2009 Aug;9(8):1876-85. doi: 10.1111/j.1600-6143.2009.02726.x. Epub 2009 Jun 26.

Supplemental Content

Support Center